Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.68 USD | +0.98% | -1.28% | -17.69% |
Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
Official Publications
SEC Filing 4K | CO | |
SEC Filing 4K | CO | |
SEC Filing 10Q-3 | CO | |
Slide show Q3 | CO | |
3rd quarter results | CO | |
SEC Filing 8K | CO | |
SEC Filing 4K | CO | |
SEC Filing 8K | CO | |
SEC Filing 4K | CO | |
SEC Filing 4K | CO | |
SEC Filing 4K | CO | |
SEC Filing 4K | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-2 | CO | |
1st-half-year results | CO | |
Slide show half-year results | CO | |
SEC Filing 4K | CO | |
Provisional calendar | CO | |
SEC Filing 4K | CO | |
SEC Filing 8K | CO | |
SEC Filing 4K | CO | |
SEC Filing 4K | CO | |
Slide show Q1 | CO | |
1st quarter results | CO | |
SEC Filing 10Q-1 | CO |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Official Publications